Literature DB >> 25593023

Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization.

Gloriane Schnabolk1, Beth Coughlin2, Kusumam Joseph2, Kannan Kunchithapautham2, Mausumi Bandyopadhyay2, Elizabeth C O'Quinn2, Tamara Nowling3, Bärbel Rohrer4.   

Abstract

PURPOSE: Complement factor B (CFB) is a required component of the alternative pathway (AP) of complement, and CFB polymorphisms are associated with age-related macular degeneration (AMD) risk. Complement factor B is made in the liver, but expression has also been detected in retina and retinal pigment epithelium (RPE)-choroid. We investigated whether production of CFB by the RPE can promote AP activation in mouse choroidal neovascularization (CNV).
METHODS: Transgenic mice expressing CFB under the RPE65 promoter were generated and crossed onto factor B-deficient (CFB-KO) mice. Biological activity was determined in vitro using RPE monolayers and in vivo using laser-induced CNV. Contribution of systemic CFB was investigated using CFB-KO reconstituted with CFB-sufficient serum.
RESULTS: Transgenic mice (CFB-tg) expressed CFB in RPE-choroid; no CFB was detected in serum. Cultured CFB-tg RPE monolayers secreted CFB apically and basally upon exposure to oxidative stress that was biologically active. Choroidal neovascularization sizes were comparable between wild-type and CFB-tg mice, but significantly increased when compared to lesions in CFB-KO mice. Injections of CFB-sufficient serum into CFB-KO mice resulted in partial reconstitution of systemic AP activity and significantly increased CNV size.
CONCLUSIONS: Mouse RPE cells express and secrete CFB sufficient to promote RPE damage and CNV. This further supports that local complement production may regulate disease processes; however, the reconstitution experiments suggest that additional components may be sequestered from the bloodstream. Understanding the process of ocular complement production and regulation will further our understanding of the AMD disease process and the requirements of a complement-based therapeutic. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  RPE-specific transgenic mouse; age-related macular degeneration; alternative complement pathway; choroidal neovascularization; complement factor B

Mesh:

Substances:

Year:  2015        PMID: 25593023      PMCID: PMC4364641          DOI: 10.1167/iovs.14-15910

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  49 in total

Review 1.  An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.

Authors:  G S Hageman; P J Luthert; N H Victor Chong; L V Johnson; D H Anderson; R F Mullins
Journal:  Prog Retin Eye Res       Date:  2001-11       Impact factor: 21.198

2.  The efficiency of pooling mRNA in microarray experiments.

Authors:  C M Kendziorski; Y Zhang; H Lan; A D Attie
Journal:  Biostatistics       Date:  2003-07       Impact factor: 5.899

3.  Gene dosage effect of the TrkB receptor on rod physiology and biochemistry in juvenile mouse retina.

Authors:  B Rohrer
Journal:  Mol Vis       Date:  2001-12-12       Impact factor: 2.367

4.  Age as an independent risk factor for severity of experimental choroidal neovascularization.

Authors:  Diego G Espinosa-Heidmann; Ivan Suner; Eleut P Hernandez; William D Frazier; Karl G Csaky; Scott W Cousins
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-05       Impact factor: 4.799

5.  The upstream region of the Rpe65 gene confers retinal pigment epithelium-specific expression in vivo and in vitro and contains critical octamer and E-box binding sites.

Authors:  A Boulanger; S Liu; A A Henningsgaard; S Yu; T M Redmond
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

6.  Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.

Authors:  Puran S Bora; Zhiwei Hu; Tongalp H Tezel; Jeong-Hyeon Sohn; Shin Goo Kang; Jose M C Cruz; Nalini S Bora; Alan Garen; Henry J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

7.  C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury.

Authors:  Maciej M Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Robert A DeAngelis; Christoph W Strey; Silvia Franchini; Rick A Wetsel; Anna Erdei; John D Lambris
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

8.  Abnormal phagocytosis by retinal pigmented epithelium that lacks myosin VIIa, the Usher syndrome 1B protein.

Authors:  Daniel Gibbs; Junko Kitamoto; David S Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

9.  Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells.

Authors:  G Shiota; D B Rhoads; T C Wang; T Nakamura; E V Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  A comparative analysis of C57BL/6J and 6N substrains; chemokine/cytokine expression and susceptibility to laser-induced choroidal neovascularization.

Authors:  Gloriane Schnabolk; Kimberly Stauffer; Elizabeth O'Quinn; Beth Coughlin; Kannan Kunchithapautham; Bärbel Rohrer
Journal:  Exp Eye Res       Date:  2014-10-13       Impact factor: 3.467

View more
  20 in total

Review 1.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

2.  Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology.

Authors:  Elisabeth Obert; Randy Strauss; Carlene Brandon; Christina Grek; Gautam Ghatnekar; Robert Gourdie; Bärbel Rohrer
Journal:  J Mol Med (Berl)       Date:  2017-01-28       Impact factor: 4.599

Review 3.  Complement factor H in AMD: Bridging genetic associations and pathobiology.

Authors:  Christopher B Toomey; Lincoln V Johnson; Catherine Bowes Rickman
Journal:  Prog Retin Eye Res       Date:  2017-09-18       Impact factor: 21.198

Review 4.  Complement Activation and Inhibition in Retinal Diseases.

Authors:  Mark E Kleinman; Jayakrishna Ambati
Journal:  Dev Ophthalmol       Date:  2015-10-26

Review 5.  Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.

Authors:  Benjamin J Kim; Dimitrios C Mastellos; Yafeng Li; Joshua L Dunaief; John D Lambris
Journal:  Prog Retin Eye Res       Date:  2020-12-13       Impact factor: 19.704

Review 6.  Inflammation and its role in age-related macular degeneration.

Authors:  Anu Kauppinen; Jussi J Paterno; Janusz Blasiak; Antero Salminen; Kai Kaarniranta
Journal:  Cell Mol Life Sci       Date:  2016-02-06       Impact factor: 9.261

7.  C3a Increases VEGF and Decreases PEDF mRNA Levels in Human Retinal Pigment Epithelial Cells.

Authors:  Qin Long; Xiaoguang Cao; Ailing Bian; Ying Li
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

Review 8.  Complement System and Potential Therapeutics in Age-Related Macular Degeneration.

Authors:  Young Gun Park; Yong Soo Park; In-Beom Kim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

9.  Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina.

Authors:  Jennifer A E Williams; Dimitris Stampoulis; Chloe E Gunter; John Greenwood; Peter Adamson; Stephen E Moss
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

10.  AICAR suppresses TNF-α-induced complement factor B in RPE cells.

Authors:  Eun Jee Chung; Nikolaos E Efstathiou; Eleni K Konstantinou; Daniel E Maidana; Joan W Miller; Lucy H Young; Demetrios G Vavvas
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.